Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen
about
Structural basis for recognition by an in vitro evolved affibodyRational Protein Engineering Guided by Deep Mutational ScanningDrugs derived from phage display: from candidate identification to clinical practiceStructural Insights into the Binding of Vascular Endothelial Growth Factor-B by VEGFR-1D2: RECOGNITION AND SPECIFICITYUltrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylationProteochemometric modeling of the antigen-antibody interaction: new fingerprints for antigen, antibody and epitope-paratope interactionAntibody engineering using phage display with a coiled-coil heterodimeric Fv antibody fragmentVascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.Tailoring in vitro evolution for protein affinity or stability.Protein engineering: navigating between chance and reason.Exploring protein-protein interactions with phage display.Molecular studies of anti-HLA-A2 using light-chain shuffling: a structural model for HLA antibody binding.Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.A general method for greatly improving the affinity of antibodies by using combinatorial librariesStructure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm.Design of synthetic antibody libraries.Guidance for the treatment of neovascular age-related macular degeneration.Affinity-matured recombinant antibody fragments analyzed by single-molecule force spectroscopyIdentification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo.Pep-3D-Search: a method for B-cell epitope prediction based on mimotope analysis.Overview on concepts and applications of Fab antibody fragments.High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.Age-related macular degeneration: current treatments.Current and emerging therapies for the treatment of age-related macular degenerationSelection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening.A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacyComputational design of antibody-affinity improvement beyond in vivo maturationThe proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1.OptCDR: a general computational method for the design of antibody complementarity determining regions for targeted epitope binding.MimoPro: a more efficient Web-based tool for epitope prediction using phage display libraries.The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration.Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.The past, present, and future of exudative age-related macular degeneration treatment.Cytokine detection by antibody-based proximity ligation.Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients.Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.
P2860
Q24564598-4A81BA64-CE1B-404B-B33B-7B69A8A21B9BQ26781349-4195EC01-EBBF-4726-B33B-BC2CF0AEFBB4Q27007101-2240D634-0B7C-4586-BDDC-6215C2069C09Q27661923-0D1F35D4-EB83-426D-948D-CFD9C5FECB75Q28392005-7358F21A-3A69-4BEB-AAD7-F2A281C42397Q28546634-FB02448F-0EA0-417B-9EF1-7A813BC83799Q28740649-765DE9DB-09EC-473A-AA2E-C5A54838D44AQ30244247-6619311A-42B7-4286-879C-5BFFB5782DB5Q30923970-FA230A5A-D582-4653-96D1-6472F345F91BQ30977386-D2E3B412-2252-4638-99BD-C2A9CD6E0AAAQ31025365-A7C94052-EB7A-467A-8195-041E15039CC5Q31123976-47F15FC8-BE54-46BE-9617-2562269167CBQ33199161-51FC4EEC-696D-436C-A19F-A37C70822108Q33205837-AB0DA2A0-4315-4304-AA3C-2F5E27BC656DQ33216580-DF725DE9-6668-4F6E-B444-1C8C1A4D1296Q33230191-50B764C1-2760-4AD8-B537-6917E9C569E6Q33265689-168B34B3-42E8-4334-B2BF-02B70B79FFA3Q33283622-15687511-BC28-4174-B580-05F1642FE677Q33291861-D4B0C59D-C87D-476C-97F2-CB6D1531701BQ33293045-176FF811-0299-465E-BD22-6CC2E12F7358Q33393258-2F68144C-0538-42CF-9984-3C3575E57586Q33393441-93D3EAFB-359A-4DC2-A0A1-BAC0D1CDD5DCQ33411367-29DC18EA-B573-4EC6-9202-188F426F509DQ33424684-5AA5630C-405C-4877-9B76-724553F7EC08Q33492348-4FA17222-E254-4E5A-A596-9F4A42CB3430Q33492370-9014C178-089C-42C1-A533-9C1D706232CFQ33566182-B224B9FB-96F8-4014-9BA8-F31A66168162Q33573612-0181DBAF-765A-4E83-A752-A8203FCE345BQ33576857-E8AC264D-3D17-44D6-9771-A20C1BDB8362Q33614283-5D90C784-B6D9-4FB6-ACC8-4359988C75E8Q33694202-7BE73C4C-F75B-46AA-8A22-EEAA079B8103Q33910596-1B0F141A-51EE-4A85-91E3-A6F2B331A829Q33971694-CB5CD511-C512-429B-9C04-265843F703FEQ34075366-D089BA3D-07FC-4156-A446-91F3CD5FF5A9Q34092454-AAEFB6FB-1537-4B5D-873B-62326D61A41AQ34115840-D45332EA-A7C5-4D41-9097-5DABDF3EE7DEQ34161956-498FE583-DB60-40D6-A102-414E30E33B12Q34322204-8B41F351-AD75-40D3-93F1-74E4A56C9B25Q34331514-4C4A3E1E-0564-4313-9BA0-572B41B1C24FQ34410824-39FE4FDA-F82C-4C83-ACB9-CAB19FDD7959
P2860
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Selection and analysis of an o ...... ed Fab in complex with antigen
@ast
Selection and analysis of an o ...... ed Fab in complex with antigen
@en
Selection and analysis of an o ...... ed Fab in complex with antigen
@nl
type
label
Selection and analysis of an o ...... ed Fab in complex with antigen
@ast
Selection and analysis of an o ...... ed Fab in complex with antigen
@en
Selection and analysis of an o ...... ed Fab in complex with antigen
@nl
prefLabel
Selection and analysis of an o ...... ed Fab in complex with antigen
@ast
Selection and analysis of an o ...... ed Fab in complex with antigen
@en
Selection and analysis of an o ...... ed Fab in complex with antigen
@nl
P2093
P3181
P356
P1476
Selection and analysis of an o ...... ed Fab in complex with antigen
@en
P2093
A M de Vos
C Wiesmann
H B Lowman
H W Christinger
P304
P3181
P356
10.1006/JMBI.1999.3192
P407
P577
1999-11-05T00:00:00Z